Dextromethorphan and guaifenesin use must be monitored meticulously in patients with "bad metabolizer" CYP2D6 enzyme levels and sufferers who are sedated. This mixture medication has a large median harmful dose (TD50) to median effective dose (ED50) ratio (or therapeutic index) in these patients. These products and solutions tend not to https://chemicalglobe.com/